Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | CHIEF MEDICAL OFFICER | September 17, 2026 | September 21, 2026 |
| IO Biotech, Inc.IOBT · Entity 8764 | Director | June 05, 2025 | June 06, 2025 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 04, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-09-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-17 · Exercise / conversion · Acquired 5,000 · Balance 30,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Common StockSEC Table I · non-derivative | Direct | 27,084 |
Reported balance
After 2026-09-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-17 · Sale · Disposed 2,916 · Balance 27,084 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F3: This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Common StockSEC Table I · non-derivative | Direct | 25,240 |
Reported balance
After 2026-09-17 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-17 · Sale · Disposed 1,844 · Balance 25,240 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F4: This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2026-09-17 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-17 · Sale · Disposed 240 · Balance 25,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2031-06-17 | Direct | 106,268 |
Reported balance
After 2026-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-17 · Exercise / conversion · Disposed 5,000 · Balance 106,268 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F7: All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F7: All of the shares subject to this option are fully vested and exercisable as of the date hereof.
IO Biotech, Inc.
Report date June 05, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-06-05 | Direct | 35,144 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 35,144 · Balance 35,144 F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.
Kura Oncology, Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03 | Direct | 35,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FIVE PRIME THERAPEUTICS, INC.
Report date March 31, 2021 · Filed April 19, 2021
Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-04-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-03-31 · Gift · Disposed 8,085 · Balance 69,547 Row 2 · 2021-04-16 · Grant · Acquired 66,000 · Balance 135,547 F1: Represents shares of performance-based restricted Common Stock (as defined below) granted to the reporting person on June 24, 2019 (the "Performance Award"). The performance conditions associated with the Performance Award have not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the Performance Award was deemed to have vested and each share of Common Stock underlying the Performance Award was converted into the right to receive the Offer Price (as defined below) in cash, without interest, minus any applicable withholding taxes. Row 3 · 2021-04-16 · Disposition to issuer · Disposed 135,547 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.89 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-16 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.69 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-04-16 · Disposition to issuer · Disposed 58,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-04-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-04-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-04-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F4: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of performance-based restricted Common Stock (as defined below) granted to the reporting person on June 24, 2019 (the "Performance Award"). The performance conditions associated with the Performance Award have not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the Performance Award was deemed to have vested and each share of Common Stock underlying the Performance Award was converted into the right to receive the Offer Price (as defined below) in cash, without interest, minus any applicable withholding taxes.
F2: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.
F3: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.
F4: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2019 Filed Feb 27, 2019 19:58 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantEmployee Stock Option (right to buy) · Derivative | 58,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001209191-19-014255 · doc4.xml · derivative · entry 3 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2029-02-24 F2 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 25, 2019, provided the reporting person provides services to the Company through each such date. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 19:58 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014255 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,971 F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 25, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:21 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 3,196 | $11.43 | $36,530.28 |
DisclosureSEC source: 0001209191-19-008148 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,971 Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 18:43 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 1,906 | $13.92 | $26,531.52 |
DisclosureSEC source: 0001209191-18-053442 · doc4.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,167 Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 18:43 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 3,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053442 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,073 F1 · shares: Represents shares of common stock that were delivered to the reporting person on September 28, 2018 upon achievement of a performance-based condition applicable to a restricted stock award granted to the reporting person on February 7, 2017. Read SEC document |
| September 01, 2018 Filed Sep 5, 2018 11:22 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 496 | $14.00 | $6,944.00 |
DisclosureSEC source: 0001209191-18-049427 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,229 Read SEC document |
| June 23, 2018 Filed Jun 26, 2018 20:16 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 1,240 | $17.38 | $21,551.20 |
DisclosureSEC source: 0001209191-18-039552 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,725 Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 14:50 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 827 | $16.26 | $13,447.02 |
DisclosureSEC source: 0001209191-18-021228 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,965.25 Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 19:18 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-18-014701 · doc4.xml · derivative · entry 3 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-25 F2 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month following February 26, 2018, provided the reporting person provides services to the Company through each such date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 19:18 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014701 · doc4.xml · nonDerivative · entry 2 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,792.25 F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 26, 2019, 2020 and 2021, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 14:05 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 1,048 | $18.42 | $19,304.16 |
DisclosureSEC source: 0001209191-18-008071 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,732.25 Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 19:11 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 376 | $34.34 | $12,911.84 |
DisclosureSEC source: 0001209191-17-051780 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,780.25 Read SEC document |
| June 23, 2017 Filed Feb 28, 2018 19:18 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 940 | $31.24 | $29,365.60 |
DisclosureSEC source: 0001209191-18-014701 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,792.25 Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:36 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-028213 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,156.25 F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of March 20, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 17:45 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $39.21 | $0.00 |
DisclosureSEC source: 0001209191-17-022378 · doc4.xml · derivative · entry 2 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,500 Underlying: Common Stock · 22,500 shares Expires 2027-03-20 F2 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month following March 20, 2017, provided the reporting person provides services to the Company through each such date. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 17:45 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022378 · doc4.xml · nonDerivative · entry 1 Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,906.25 F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of March 20, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.